Vanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor ConferencesPRNewsWire • 05/12/21
Amazon, Caterpillar, Disney, EA, Target and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 05/12/21
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Vanda Pharmaceuticals (VNDA) Surpasses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/05/21
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/28/21
Vanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021PRNewsWire • 04/20/21
Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to DismissBusiness Wire • 03/11/21
Vanda Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite RatingInvestors Business Daily • 02/12/21
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/11/21
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial ResultsPRNewsWire • 02/10/21
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021PRNewsWire • 02/02/21
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis SyndromePRNewsWire • 12/01/20
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/29/20
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic ConjunctivitisPRNewsWire • 10/26/20
Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020PRNewsWire • 10/21/20